Known hypersensitivity to dabigatran etexilate or dabigatran or any of the excipients of the preparation. Severe renal impairment (CrCl <30 ml / min).
Concomitant treatment with inhibitor of P-gp, such as quinidine, dronedarone, ritonavir, tipranavir, nelfinavir, saquinavir, cyclosporin and tacrolimus, but also systemic treatment with ketoconazole, itraconazole or voriconazole (see "Interactions").
Manifestation of bleeding, patients with bleeding diathesis or spontaneous or pharmacological impairment of haemostasis.
Organic lesions with risk of clinically significant bleeding, including a history of hemorrhagic stroke in the last 6 months.
Liver failure or liver disease can have an impact on survival (liver failure in scores of Child-Pugh A, B and C).
